Corrigendum to “Early treatment with xenon protects against the cold ischemia associated with chronic allograft nephropathy in rats.” Kidney International 2013;85:112–123 (Early treatment with xenon protects against the cold ischemia associated with chronic allograft nephropathy in rats (2014) 85(1) (112–123), (S0085253815561589), (10.1038/ki.2013.334));Early treatment with xenon protects against the cold ischemia associated with chronic allograft nephropathy in rats

Kidney International

Volumn 85, Issue 1, 2014, Pages 112-123

  Zhao, Hailin ^a   Luo, Xianghong ^a,b   Zhou, Zhaowei ^a   Liu, Juying ^b   Tralau Stewart, Catherine ^c   George, Andrew J T ^c   Ma, Daqing ^a,b  

^a Section of Anaesthetics Pain Medicine and Intensive Care Department of Surgery and Cancer   (United Kingdom)

^b HUBEI UNIVERSITY OF MEDICINE   (China)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

chronic allograft nephropathy; cold ischemia; delayed graft function; graft protection; xenon

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; XENON;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL STRAIN HK 2; CHRONIC ALLOGRAFT NEPHROPATHY; COLD ISCHEMIA; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROSIS; GRAFT RECIPIENT; HUMAN; HUMAN CELL; HYPOTHERMIA; HYPOXIA; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; KIDNEY TUBULE CELL; LYMPHOCYTIC INFILTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; REOXYGENATION; REPERFUSION INJURY; T LYMPHOCYTE; UPREGULATION; WESTERN BLOTTING;

ANESTHETICS, INHALATION; ANIMALS; CELL LINE; COLD ISCHEMIA; DRUG EVALUATION, PRECLINICAL; HUMANS; INSULIN-LIKE GROWTH FACTOR I; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; RATS; RATS, INBRED F344; RATS, INBRED LEW; RECEPTOR, IGF TYPE 1; REPERFUSION INJURY; XENON;

EID: 84891556593     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2024.07.017     Document Type: Erratum

References (33)

1. Li C, Yang CW. The pathogenesis and treatment of chronic allograft nephropathy. Nat Rev Nephrol 2009; 5: 513-519.
2. Paul LC. Chronic allograft nephropathy: an update. Kidney Int 1999; 56: 783-793. (Pubitemid 29411708)
3. Nankivell BJ, Chapman Jr. Chronic allograft nephropathy: current concepts and future directions. Transplantation 2006; 81: 643-654.
4. Tantravahi J, Womer KL, Kaplan B. Why hasn't eliminating acute rejection improved graft survival? Annu Rev Med 2007; 58: 369-385. (Pubitemid 46706521)
5. Perico N, Cattaneo D, Sayegh MH et al. Delayed graft function in kidney transplantation. Lancet 2004; 364: 1814-1827. (Pubitemid 39488068)
6. Sanders RD, Ma D, Maze M. Xenon: elemental anaesthesia in clinical practice. Br Med Bull 2004; 71: 115-135. (Pubitemid 40478225)
7. Ma D, Hossain M, Pettet GK et al. Xenon preconditioning reduces brain damage from neonatal asphyxia in rats. J Cereb Blood Flow Metab 2006; 26: 199-208. (Pubitemid 43151576)
8. Ma D, Hossain M, Chow A et al. Xenon and hypothermia combine to provide neuroprotection from neonatal asphyxia. Ann Neurol 2005; 58: 182-193. (Pubitemid 41098876)
9. Weber NC, Toma O, Wolter JI et al. The noble gas xenon induces pharmacological preconditioning in the rat heart in vivo via induction of PKC-epsilon and p38 MAPK. Br J Pharmacol 2005; 144: 123-132. (Pubitemid 40188554)
10. Preckel B, Mullenheim J, Moloschavij A et al. Xenon administration during early reperfusion reduces infarct size after regional ischemia in the rabbit heart in vivo. Anesth Analg 2000; 91: 1327-1332.
11. Ma D, Lim T, Xu J et al. Xenon preconditioning protects against renal ischemic-reperfusion injury via HIF-1alpha activation. J Am Soc Nephrol 2009; 20: 713-720.
12. Mairet-Coello G, Tury A, DiCicco-Bloom E. Insulin-like growth factor-1 promotes G(1)/S cell cycle progression through bidirectional regulation of cyclins and cyclin-dependent kinase inhibitors via the phosphatidylinositol 3-kinase/Akt pathway in developing rat cerebral cortex. J Neurosci 2009; 29: 775-788.
13. Ren M, Zhong X, Ma CY et al. Insulin-like growth factor-1 promotes cell cycle progression via upregulation of cyclin D1 expression through the phosphatidylinositol 3-kinase/nuclear factor-kappaB signaling pathway in FRTL thyroid cells. Acta Pharmacol Sin 2009; 30: 113-119.
14. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-732. (Pubitemid 37328811)
15. Bonventre JV. Dedifferentiation and proliferation of surviving epithelial cells in acute renal failure. J Am Soc Nephrol 2003; 14(Suppl 1): S55-S61. (Pubitemid 36687041)
16. Guo JK, Cantley LG. Cellular maintenance and repair of the kidney. Annu Rev Physiol 2010; 72: 357-376.
17. Parrizas M, Saltiel AR, LeRoith D. Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3'-kinase and mitogen-Activated protein kinase pathways. J Biol Chem 1997; 272: 154-161. (Pubitemid 27021138)
18. Beauchamp MC, Yasmeen A, Knafo A et al. Targeting insulin and insulinlike growth factor pathways in epithelial ovarian cancer. J Oncol 2010; 2010: 257058.
19. Li Q, Li B, Wang X et al. Overexpression of insulin-like growth factor-1 in mice protects from myocyte death after infarction, attenuating ventricular dilation, wall stress, and cardiac hypertrophy. J Clin Invest 1997; 100: 1991-1999. (Pubitemid 27459352)
20. Davis ME, Hsieh PC, Takahashi T et al. Local myocardial insulin-like growth factor 1 (IGF-1) delivery with biotinylated peptide nanofibers improves cell therapy for myocardial infarction. Proc Natl Acad Sci USA 2006; 103: 8155-8160. (Pubitemid 43801068)
21. Miller SB, Martin DR, Kissane J et al. Insulin-like growth factor I accelerates recovery from ischemic acute tubular necrosis in the rat. Proc Natl Acad Sci USA 1992; 89: 11876-11880. (Pubitemid 23004747)
22. Ding H, Kopple JD, Cohen A et al. Recombinant human insulin-like growth factor-I accelerates recovery and reduces catabolism in rats with ischemic acute renal failure. J Clin Invest 1993; 91: 2281-2287. (Pubitemid 23141506)
23. Fingar DC, Richardson CJ, Tee AR et al. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol 2004; 24: 200-216. (Pubitemid 38010048)
24. Goto T, Suwa K, Uezono S et al. The blood-gas partition coefficient of xenon may be lower than generally accepted. Br J Anaesth 1998; 80: 255-256. (Pubitemid 28069784)
25. Lynch C 3rd, Baum J, Tenbrinck R. Xenon anesthesia. Anesthesiology 2000; 92: 865-868. (Pubitemid 30130190)
26. Goto T, Saito H, Shinkai M et al. Xenon provides faster emergence from anesthesia than does nitrous oxide-sevoflurane or nitrous oxideisoflurane. Anesthesiology 1997; 86: 1273-1278. (Pubitemid 27262303)
27. Abraini JH, David HN, Lemaire M. Potentially neuroprotective and therapeutic properties of nitrous oxide and xenon. Ann NY Acad Sci 2005; 1053: 289-300. (Pubitemid 43031108)
28. David HN, Haelewyn B, Rouillon C et al. Neuroprotective effects of xenon: a therapeutic window of opportunity in rats subjected to transient cerebral ischemia. FASEB J 2008; 22: 1275-1286. (Pubitemid 351519980)
29. Bernhardt WM, Gottmann U, Doyon F et al. Donor treatment with a PHDinhibitor activating HIFs prevents graft injury and prolongs survival in an allogenic kidney transplant model. Proc Natl Acad Sci USA 2009; 106: 21276-21281.
30. Giral M, Nguyen JM, Karam G et al. Impact of graft mass on the clinical outcome of kidney transplants. J Am Soc Nephrol 2005; 16: 261-268. (Pubitemid 43073181)
31. Nishimura Y, Tomikawa S, Beck Y et al. Kidney graft weight as an important risk factor for long-Term graft survival. Transplant Proc 1998; 30: 107-110. (Pubitemid 28090330)
32. Seun Kim Y, Soo Kim M, Suk Han D et al. Evidence that the ratio of donor kidney weight to recipient body weight, donor age, and episodes of acute rejection correlate independently with live-donor graft function. Transplantation 2002; 74: 280-283. (Pubitemid 34810298)
33. Wynn TA. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol 2004; 4: 583-594.